Literature DB >> 7521822

Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease.

O H Nielsen1, E Langholz, J Hendel, J Brynskov.   

Abstract

Intercellular adhesion molecule (ICAM)-1 promotes the initial interaction between macrophages and T cells during immune activation. We have measured serum levels of soluble ICAM-1 (sICAM-1) by ELISA in 27 patients with ulcerative colitis (UC), 31 with Crohn's disease (CD), and 29 healthy subjects. The median sICAM-1 serum concentration was significantly increased in inflammatory bowel disease (IBD) patients (355 ng/ml, range 195-855) compared to controls (245 ng/ml, 155-580) (P = 0.001). Variance analysis for trend showed that sICAM-1 levels were significantly higher in patients with active CD and UC, compared to those with inactive disease and controls (P = 0.00002). The concentration of sICAM-1 was higher in CD patients (365 ng/ml 230-470) compared to UC (300 ng/ml 195-855) (P = 0.01). Furthermore, weak but significant correlations were found between serum levels of sICAM-1 and: soluble IL-2 receptors, orosomucoid, and C-reactive protein. It is suggested that increased circulating sICAM-1 levels may reflect increased adhesiveness and signal transmission across cells, probably as a result of shedding of the parent molecule during local cellular immunoresponses in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521822     DOI: 10.1007/bf02088125

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Expression of adhesion molecules on circulating leucocytes in patients with inflammatory bowel disease.

Authors:  S M Greenfield; A Hamblin; N A Punchard; R P Thompson
Journal:  Clin Sci (Lond)       Date:  1992-08       Impact factor: 6.124

Review 2.  Role of lymphocyte adhesion receptors in transient interactions and cell locomotion.

Authors:  M L Dustin; T A Springer
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  Surface expression of Gp 165/95, the complement receptor CR3, as a marker of disease activity in systemic Lupus erythematosus.

Authors:  J P Buyon; N Shadick; R Berkman; P Hopkins; J Dalton; G Weissmann; R Winchester; S B Abramson
Journal:  Clin Immunol Immunopathol       Date:  1988-01

4.  Serum antibodies to Bacteroides species in chronic inflammatory bowel disease.

Authors:  M Tvede; S Bondesen; O H Nielsen; S N Rasmussen
Journal:  Scand J Gastroenterol       Date:  1983-09       Impact factor: 2.423

5.  Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease.

Authors:  G Malizia; A Calabrese; M Cottone; M Raimondo; L K Trejdosiewicz; C J Smart; L Oliva; L Pagliaro
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

6.  Light and electron microscopic immunolocalization of endothelial leucocyte adhesion molecule-1 in inflammatory bowel disease. Morphological evidence of active synthesis and secretion into vascular lumen.

Authors:  H Ohtani; S Nakamura; Y Watanabe; K Fukushima; T Mizoi; M Kimura; N Hiwatashi; H Nagura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Immune activation genes in inflammatory bowel disease.

Authors:  T Matsuura; G A West; K R Youngman; J S Klein; C Fiocchi
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

8.  Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.

Authors:  J Brynskov; N Tvede
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

9.  Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease.

Authors:  J Brynskov; N Tvede; C B Andersen; M Vilien
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

10.  Soluble interleukin-2 receptors in ulcerative colitis.

Authors:  O H Nielsen; J Brynskov
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

View more
  14 in total

1.  Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease.

Authors:  B Vainer; O H Nielsen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease.

Authors:  Yuji Naito; Tomohisa Takagi; Toshikazu Yoshikawa
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

3.  Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease.

Authors:  M Göke; J C Hoffmann; J Evers; H Krüger; M P Manns
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

4.  Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis.

Authors:  F Bendjelloul; P Malý; V Mandys; M Jirkovská; L Prokesová; L Tucková; H Tlaskalová-Hogenová
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

5.  Quantification of mucosal leucocyte endothelial cell interaction by in vivo fluorescence microscopy in experimental colitis in mice.

Authors:  S Farkas; H Herfarth; M Rössle; J Schroeder; M Steinbauer; M Guba; A Beham; J Schölmerich; K W Jauch; M Anthuber
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

6.  Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

Authors:  Hamed Laroui; Emilie Viennois; Bo Xiao; Brandon S B Canup; Duke Geem; Timothy L Denning; Didier Merlin
Journal:  J Control Release       Date:  2014-05-05       Impact factor: 9.776

7.  Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.

Authors:  F Magro; F Araujo; P Pereira; E Meireles; M Diniz-Ribeiro; F Tavarela Velosom
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

8.  High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis.

Authors:  László Bene; George Füst; Béla Fekete; Agota Kovács; Laura Horváth; Zoltán Prohászka; Kata Miklós; Gábor Pálos; Mohamed Daha; Henriette Farkas; Lilian Varga
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

9.  Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis.

Authors:  O H Nielsen; J Brynskov; B Vainer
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

10.  Elevated serum values of procollagen III peptide (PIIIP) in patients with ulcerative colitis who will develop pseudopolyps.

Authors:  Zarko Babic; Vjekoslav Jagić; Zvonko Petrović; Ante Bilić; Kapetanović Dinko; Goranka Kubat; Rosana Troskot; Mira Vukelić
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.